Table 3.
Characteristics by Death Status Among Participants in Post Week-4 Mortality Analysis
| Death by Week 48 | CC Analysis | MI Analysis3 | |||
|---|---|---|---|---|---|
| Characteristic | Yes (N=43) |
No (N=703) |
Adjusted HR (95% CI)1,2 |
Adjusted HR (95% CI)1,2 |
|
| Age (years) | Mean | 38.3 | 36.5 | 0.96 (0.93–1.00) | 0.96 (0.93–0.99) |
| Median (IQR) | 37 (31, 47) | 36 (30, 41) | |||
| BMI (kg/m^2) | Median (IQR) | 19.1 (17.5, 21.4) | 20.4 (18.3, 22.9) | ||
| 18.5–25 vs. > 25 | 5.19 (0.69–39.31) | 1.66 (0.56–4.92) | |||
| < 18.5 vs. > 25 | 4.57 (0.58–36.00) | 1.23 (0.39–3.91) | |||
| Hemoglobin (g/dL) | Median (IQR) | 10.6 (8.6, 11.9) | 11.3 (10.1, 12.6) | 1.32 (1.12–1.55) | 1.32 (1.15–1.51) |
| Absolute CD4 Count | Median (IQR) | 16 (9, 24) | 19 (9, 32) | 1.30 (1.05–1.60)4 | 1.43 (1.17–1.75)4 |
| Log 10 HIV-1 RNA/mL | Median (IQR) | 5.1 (4.7, 5.8) | 5.3 (4.9, 5.7) | 0.62 (0.38–1.02) | 0.59 (0.37–0.93) |
| Sex | Male | 22 (51%) | 372 (53%) | Reference | Reference |
| Female | 21 (49%) | 331 (47%) | 1.48 (0.75–2.91) | 1.20 (0.67–2.15) | |
| Change in CD4 Count from Week 0 to Week 4 | Median (IQR) | 26 (3, 43) | 56 (22, 96) | 1.25 (1.06–1.47)5 | 1.20 (1.01–1.42)5 |
| Change in log 10 HIV-1 RNA from Week 0 to Week 4 | Median (IQR) | −2.7 (−3.1, −0.4) | −2.7 (−3.0, −2.4) | 0.50 (0.35–0.74) | 0.53 (0.37–0.76) |
| HIV-1 RNA < 400 at Week 4 | Yes | 20 (47%) | 335 (48%) | Reference | Reference |
| No | 23 (53%) | 368 (52%) | 0.45 (0.17–1.18) | 0.63 (0.26–1.55) | |
| New WHO Clinical Stage 3 or 4 Conditions by Week 4 | Yes | 6 (14.0%) | 37 (5.3%) | 2.76 (1.11–6.88) | 2.03 (0.87–4.72) |
| No | 37 (86.0%) | 666 (94.7%) | Reference | Reference | |
1
Hazard ratios for continuous variables are given per unit decrease, unless otherwise noted
2
Hazard ratios adjusted for all variables included in this table
3
Additional variables in imputation model: albumin, absolute neutrophil count, neutrophils (%), and white blood cell count
4
Hazard ratio is per 10 unit decrease
5
Hazard ratio is per 20 unit decrease